Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

MDS completes divestiture of instrument division to Danaher for US$650 million

Fasken
Reading Time 1 minute read Subscribe
Client

MDS Inc.

On February 1, 2010, MDS Inc. (TSX: MDS; NYSE: MDZ) announced that it had completed the divestiture of its MDS Analytical Technologies business to Danaher Corporation (NYSE: DHR) for US$650 million in cash.

MDS intends to return approximately $400 million to $450 million of the sale proceeds to shareholders by way of a share buyback through a Substantial Issuer Bid, expected to be initiated in the next 30 days.

Fasken Martineau was Canadian counsel to MDS in this transaction with a team led by Scott Conover and Richard Steinberg and including, among others, Aaron Atkinson, Tracy Hooey, John Beardwood and Alex Nikolic (M&A); Anthony Baldanza and Mark Magro (competition); Samuel Rickett (strategic counsel); Armand Benitah (IP); Ralph Nero (employment); and Ross Gascho (pensions). Robert Harrison and Berkley Sells (litigation) acted in connection with a third party application to enjoin the transaction.

    Subscribe

    Receive email updates from our team

    Subscribe